FrancophonIA/ELRC3.0 huggingface dataset:
English: No effect on umeclidinium AUC or Cmax was observed at a dose 4-fold higher than the therapeutic dose.
Estonian: Terapeutilisest annusest neli korda suurema annuse kasutamisel ei täheldatud toimet umeklidiiniumi AUC või Cmax väärtustele.
English: Hypersensitivity reactions including: Rash, urticaria and pruritus
Estonian: Immuunsüsteemi häired Ülitundlikkushäired, sealhulgas: Lööve, urtikaaria ja kihelus
English: Rolufta Ellipta 55 mcg inhalation powder umeclidinium (umeclidinium bromide)
Estonian: Rolufta Ellipta 55 g inhalatsioonipulber umeklidiinium (umeklidiiniumbromiid)
English: Keep out of the sight and reach of children.
Estonian: Hoida laste eest varjatud ja kättesaamatus kohas.
English: Absorption
Estonian: Imetamine
English: EXPIRY DATE
Estonian: Sage Aeg-ajalt
English: How to store Rolufta Ellipta
Estonian: Kuidas Rolufta Elliptat säilitada
English: Breast-feeding
Estonian: Nasofarüngiit
English: Desiccant
Estonian: Lööve
English: ANNEX II
Estonian: III LISA
English: Ireland.
Estonian: Iirimaa
English: If you use more Rolufta Ellipta than you should
Estonian: Kui te unustate Rolufta Elliptat kasutada
English: LIST OF EXCIPIENTS
Estonian: KOKi ägenemised
English: Umeclidinium bromide has not been evaluated in subjects with severe hepatic impairment.
Estonian: Raske maksakahjustusega isikutel ei ole umeklidiiniumbromiidi kasutamist hinnatud.
English: Open the cover when ready to take a dose.
Estonian: Kui olete valmis annust manustama, avage kate.
English: The tray is sealed with a peelable foil lid.
Estonian: Alus on hermeetiliselt suletud eemaldatava fooliumkattega.
English: • cough
Estonian: • pearinglus.
English: Immune system disorders
Estonian: Infolehe sisukord
English: 28 patches (7 x 2 mg/24h, 7 x 4 mg/24h, 7 x 6 mg/24h, 7 x 8 mg/24h)
Estonian: Transdermaalne plaaster transdermaalset plaastrit (7 x 2 mg/24h, 7 x 4 mg/24h, 7 x 6 mg/24h, 7 x 8 mg/24h)
English: Annex A
Estonian: LISA A
English: PE/Alu/ ET copolymer/paper)
Estonian: Leganto -
English: Transdermal patch Transdermal use sachet (paper/LDPE/alu/ET copolymer PE/Alu/ET copolymer/paper)
Estonian: Tugevus Ravimvorm Manustamistee Pakendi iseloomustus
English: 20 January 2009
Estonian: 20. jaanuar 2010
English: The main studies involved relatively young patients and therefore no conclusion could be drawn on how the medicine would work in other age groups.
Estonian: Põhiuuringutes osalesid suhteliselt noored patsiendid ja seetõttu ei saa teha järeldusi ravimi toime kohta teistes vanuserühmades.
English: What was the recommendation of the CHMP at that time?
Estonian: Milline oli sel ajal inimravimite komitee soovitus?
English: There was also insufficient information on the safety of the medicine compared with medicines containing only one of the active substances.
Estonian: Lisaks oli ravimi ohutusteave ebapiisav, võrreldes ainult ühe toimeainega ravimitega.
English: The main measures of effectiveness were based on the level of pain relief after two hours, the number of patients who were asleep after one hour and how long the patients slept.
Estonian: Efektiivsuse põhinäitajad lähtusid sellest, kui palju oli valu leevenenud kaks tundi hiljem, samuti patsientide arvust, kes magasid tund aega pärast ravimi manustamist, ning nende une kestusest.
English: Questions and answers
Estonian: Teabedokument
English: The letter from the company notifying the CHMP of the withdrawal of the application is available here.
Estonian: Ettevõtte kiri, milles ta teatab inimravimite komiteele oma taotluse tagasivõtmisest, on avaldatud siin.
English: The company presented the results of three main studies involving around 900 adults with pain.
Estonian: Uuringutes osales ligikaudu 900 valuga täiskasvanut.
English: What documentation did the company present to support its application?
Estonian: Mis dokumendid esitas ettevõte oma taotluse toetuseks?
English: When taken together, the two active substances were expected to provide benefits for patients with pain who have difficulty sleeping because of the pain.
Estonian: Kahe toimeaine koos kasutamisel peaks need olema kasulikud patsientidele, kes ei saa valu tõttu magada.
English: What are the consequences for patients in clinical trials or compassionate use programmes?
Estonian: Kuidas mõjutab tagasivõtmine praegu kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: After the CHMP had assessed the company's responses to the questions, there were still some unresolved issues.
Estonian: Inimravimite komitee oli ettevõttele esitatud küsimuste vastused läbi vaadanud, kuid mõni küsimus oli veel lahendamata.
English: It was to be available as capsules.
Estonian: Ravimit kavatseti turustada kapslitena.
English: Its main action is to block receptors for histamine, which is involved in inflammation and allergic reactions, but it also leads to drowsiness which helps to improve sleep.
Estonian: See blokeerib histamiiniretseptoreid, mis osalevad põletiku- ja allergiareaktsioonides, ning tekitavad unisust, mis aitab parandada und.
English: The studies compared the medicine with placebo (a dummy treatment) and a medicine containing ibuprofen alone.
Estonian: Uuringutes võrreldi ravimit platseeboga (toimeta ravim) ning ainult ibuprofeeni sisaldava ravimiga.
English: The application was withdrawn at ‘day 180'.
Estonian: Taotluse menetlemine oli kestnud 180 päeva, kui ettevõte võttis taotluse tagasi.
English: What were the reasons given by the company for withdrawing the application?
Estonian: Mis põhjustel võttis ettevõte taotluse tagasi?
English: How far into the evaluation was the application when it was withdrawn?
Estonian: Mis järgus oli müügiloa taotluse hindamine, kui see tagasi võeti?
English: This means that the CHMP had evaluated the documentation provided by the company and formulated a list of questions.
Estonian: Inimravimite komitee oli hinnanud ettevõtte esitatud dokumente ja koostanud ettevõttele vastamiseks küsimused.
English: Ibuprofen is a painkiller that belongs to the class non-steroidal anti-inflammatory drugs (NSAIDs).
Estonian: Ibuprofeen on valuvaigisti, mis kuulub mittesteroidsete põletikuvastaste ravimite klassi (NSAID).
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Ibuprofen/Diphenhydramine Hydrochloride Wyeth could not have been approved.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjuseid ettevaatlikkuseks ning oli esialgsel seisukohal, et ravimi Ibuprofen/Diphenhydramine Hydrochloride Wyeth müügiluba ei saa anda.
English: Diphenhydramine hydrochloride is an antihistamine.
Estonian: Difeenhüdramiinhüdrokloriid on antihistamiin.
English: Summary of the application at the time of withdrawal
Estonian: Tagasivõetava taotluse kokkuvõte
English: On 7 January 2010, Wyeth Consumer Healthcare officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Ibuprofen/Diphenhydramine Hydrochloride Wyeth, for use in the treatment of mild to moderate pain in adults who are having difficulty sleeping because of the pain.
Estonian: 7. jaanuaril 2010 teatas Wyeth Consumer Healthcare ametlikult inimravimite komiteele oma soovist võtta tagasi täiskasvanutel unehäireid põhjustava nõrga või mõõduka valu leevendamiseks kasutada kavatsetud ravimi Ibuprofen/Diphenhydramine Hydrochloride Wyeth müügiloa taotlus
English: Ibuprofen/Diphenhydramine Hydrochloride Wyeth is a medicine that contains the active substances ibuprofen and diphenhydramine hydrochloride.
Estonian: Ibuprofen/Diphenhydramine Hydrochloride Wyeth on ravim, mis sisaldab toimeainena ibuprofeeni ja difeenhüdramiinhüdrokloriidi.
English: Ibuprofen is found in medicines used to treat pain, inflammation and fever.
Estonian: Ibuprofeeni kasutatakse valuvaigistites, põletiku- ja palavikuravimites.
English: The CHMP noted that the applicant had not shown enough evidence that there was a relevant advantage of using Ibuprofen/Diphenhydramine Hydrochloride Wyeth over using ibuprofen alone.
Estonian: Inimravimite komitee märkis, et müügiloa taotleja ei ole toonud piisavalt tõendeid ravimi Ibuprofen/Diphenhydramine Hydrochloride Wyeth kasutamise eeliste kohta, võrreldes ainult ibuprofeeni kasutamisega.
English: Ibuprofen/Diphenhydramine Hydrochloride Wyeth contains two active substances that have been available in the European Union for many years in commonly used non-prescription medicines.
Estonian: Ibuprofen/Diphenhydramine Hydrochloride Wyeth sisaldab kaht toimeainet, mida on Euroopa Liidus turustatud aastaid käsimüügiravimitena.
English: Because Ibuprofen/Diphenhydramine Hydrochloride Wyeth was intended to be available without a prescription, the Committee requested more information on how it would interact with other medicines.
Estonian: Et ravimit Ibuprofen/Diphenhydramine Hydrochloride Wyeth kavatseti turustada käsimüügiravimina, nõudis komitee lisateavet selle koostoime kohta teiste ravimitega.
English: Diphenhydramine hydrochloride is found in medicines used to treat allergies, cough and sleep problems.
Estonian: Difenhüdramiin hüdrokloriidi kasutatakse allergia-, köha- ning unetusravimites.
English: What is Ibuprofen/Diphenhydramine Hydrochloride Wyeth?
Estonian: Mis on Ibuprofen/Diphenhydramine Hydrochloride Wyeth?
English: It was expected to be used without prescription.
Estonian: Seda kavatseti kasutada käsimüügiravimina.
English: Ibuprofen/Diphenhydramine Hydrochloride Wyeth was expected to be used for the short-term treatment of mild to moderate pain in adults who are having difficulty sleeping because of the pain.
Estonian: Ravimit Ibuprofen/Diphenhydramine Hydrochloride Wyeth kavatseti kasutada täiskasvanutel unehäireid põhjustava nõrga või mõõduka valu lühiajaliseks raviks.
English: The company informed the CHMP that at present there are no ongoing clinical trials or compassionate use programmes with Ibuprofen/Diphenhydramine Hydrochloride Wyeth.
Estonian: Ettevõte teatas inimravimite komiteele, et ravimi Ibuprofen/Diphenhydramine Hydrochloride Wyethkliinilisi uuringuid ega ravimi eriloaga kasutamise programme praegu ei toimu.
English: It works by blocking an enzyme called cyclo-oxygenase, which produces prostaglandins, substances that are involved in the inflammation and pain.
Estonian: See blokeerib prostaglandiine tootvat ensüümi tsüklooksügenaasi.
English: What was Ibuprofen/Diphenhydramine Hydrochloride Wyeth expected to be used for?
Estonian: Milline on ravimi Ibuprofen/Diphenhydramine Hydrochloride Wyeth eeldatav toime?
English: The effects of Ibuprofen/Diphenhydramine Hydrochloride Wyeth were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti ravimi Ibuprofen/Diphenhydramine Hydrochloride Wyeth toimet muude katsetega.
English: The recommended dose is one tablet once daily with a meal.
Estonian: Soovitatav annus on üks tablett üks kord ööpäevas koos söögiga.
English: Juluca must not be used with the following medicines because they may reduce its effectiveness:
Estonian: Julucat ei tohi kasutada koos järgmiste ravimitega, kuna need võivad vähendada selle efektiivsust:
English: Further information on Juluca can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Juluca kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Juluca?
Estonian: Mis meetmed võetakse, et tagada Juluca ohutu ja efektiivne kasutamine?
English: Other information about Juluca
Estonian: Muu teave Juluca kohta
English: Both active substances are already available in the European Union: dolutegravir has been authorised since 2014 and rilpivirine has been authorised since 2011.
Estonian: Mõlemaid toimeaineid juba turustatakse Euroopa Liidus: dolutegraviiril on müügiluba alates 2014. aastast ja rilpiviriinil 2011. aastast.
English: It does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: See ei ravi HIVnakkust ega AIDS-i välja, kuid võib immuunsüsteemi kahjustumist ning AIDS-iga seotud nakkuste ja haiguste tekkimist edasi lükata.
English: Juluca (dolutegravir / rilpivirine)
Estonian: Juluca (dolutegraviir/rilpiviriin)
English: What is Juluca and what is it used for?
Estonian: Mis on Juluca ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Juluca are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Juluca kasutamise kohta pidevat järelevalvet.
English: The side effects of Juluca are well known and manageable.
Estonian: Juluca kõrvalnähud on hästi teada ja hallatavad.
English: In this way, Juluca helps to prevent the spread of HIV-1 and keep the amount of the virus in the blood at a low level.
Estonian: Sel viisil aitab Juluca ennetada HIV-1 levikut ja hoida viiruse sisalduse veres väikese.
English: The Agency decided that Juluca's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Juluca kasulikkus on suurem kui sellega kaasnevad riskid, ja lubati ravimi kasutamine ELis.
English: Side effects reported with Juluca are carefully evaluated and any necessary action taken to protect patients.
Estonian: Juluca kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Because Juluca does not contain an NRTI, it is free of long-term side effects caused by NRTIs.
Estonian: Kuna Juluca ei sisalda NRTId, ei kaasne sellega NRTIde põhjustatavaid pikaajalisi kõrvalnähte.
English: • rifampicin, rifapentine (antibiotics);
Estonian: • rifampitsiin, rifapentiin (antibiootikumid);
English: The most serious side effects (which may affect up to 1 in 100) include allergic reactions that include rash or liver damage.
Estonian: Kõige raskemad kõrvalnähud (võivad esineda kuni 1 patsiendil 100st) on allergilised reaktsioonid, mis avalduvad lööbe või maksakahjustusena.
English: For more information about using Juluca, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Juluca kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: It is not suitable for patients in whom any HIV medicine has stopped working or who are infected with HIV that is resistant to medicines that work in the same way as Juluca's active substances.
Estonian: See ei sobi patsientidele, kellel mis tahes muu HIV-ravim enam ei toimi või kellel HIV on resistentne ravimitele, millel on Juluca toimeainetega sama toimemehhanism.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Juluca have been included in the summary of product characteristics and the package leaflet.
Estonian: Juluca ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Juluca?
Estonian: Mis riskid Julucaga kaasnevad?
English: The proportion of patients whose viral load was below 50 copies/ml after 48 weeks was the same for patients switching compared with those remaining on the current medicines (95% in both cases).
Estonian: Nende patsientide osakaal, kelle viiruskoormus oli 48 nädala järel alla 50 koopia/ml, oli ravi vahetanud patsientide rühmas sama mis nende patsientide seas, kes ravi ei vahetanud (mõlemal juhul 95%).
English: The studies involved a total of 1,028 patients whose HIV infection was well controlled for at least 6 months on a combination of three HIV medicines that included a class of HIV medicines called nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs).
Estonian: Uuringutes osales kokku 1028 patsienti, kelle HIVnakkus oli vähemalt 6 kuu vältel olnud piisava kontrolli all kombinatsiooniga kolmest HIV-ravimist, sh nukleosiid- (või nukleotiid-) pöördtranskriptaasi inhibiitorid (NRTId, teatav HIV-ravimite klass).
English: The most common side effects with Juluca are diarrhoea and headache.
Estonian: Juluca kõige sagedamad kõrvalnähud on kõhulahtisus ja peavalu.
English: The active substances in Juluca are dolutegravir and rilpivirine.
Estonian: Juluca toimeained on dolutegraviir ja rilpiviriin.
English: Two main studies found that the combination of dolutegravir and rilpivirine (the active substances in Juluca) was effective for keeping HIV infection under control.
Estonian: Kahes põhiuuringus tõendati, et dolutegraviiri ja rilpiviriini (Juluca toimeained) kombinatsioon on efektiivne HIV-nakkuse kontrolli all hoidmisel.
English: The European Medicines Agency considered that Juluca's effectiveness was comparable to that of combination treatment with three HIV medicines that include NRTIs.
Estonian: Euroopa Ravimiamet oli arvamusel, et Juluca efektiivsus oli võrreldav kolme HIV-ravimit (sh NRTIsid) sisaldanud kombinatsioonravi efektiivsusega.
English: Juluca is a HIV medicine used to treat adults infected with human immunodeficiency virus-1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Juluca on HIV-ravim, mida kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese I tüüpi immuunpuudulikkuse viiruse (HIV-1) nakkuse raviks täiskasvanutel.
English: Juluca is only used for patients whose levels of HIV-1 in the blood (viral load) have been below 50 copies/ml for at least 6 months on their current HIV treatment combination.
Estonian: Julucat kasutatakse ainult patsientidel, kellel on olemasoleva HIV-raviskeemi kasutamisel püsinud HIV1-sisaldus veres (viiruskoormus) vähemalt 6 kuu vältel alla 50 koopia/ml.
English: • omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole (proton pump inhibitors for reducing stomach acid);
Estonian: • omeprasool, esomeprasool, lansoprasool, pantoprasool, rabeprasool (prootonpumba inhibiitorid maohappe erituse vähendamiseks);
English: How does Juluca work?
Estonian: Kuidas Juluca toimib?
English: For the full list of restrictions and side effects of Juluca, see the package leaflet.
Estonian: Juluca kohta teatatud piirangute ja kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Dolutegravir, an integrase inhibitor, blocks an enzyme called integrase while rilpivirine, a non-nucleoside reverse-transcriptase inhibitor, blocks the activity of another enzyme called reverse transcriptase.
Estonian: Integraasi inhibiitor dolutegraviir blokeerib integraasi (teatav ensüüm) toime ning mittenukleosiid-pöördtranskriptaasi inhibiitor rilpiviriin blokeerib pöördtranskriptaasi (samuti ensüüm) toime.
English: How is Juluca used?
Estonian: Kuidas Julucat kasutatakse?
English: An overview of Juluca and why it is authorised in the EU
Estonian: Ülevaade ravimist Juluca ja ELis müügiloa väljastamise põhjendus
English: • carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines for epilepsy);
Estonian: • karbamasepiin, okskarbasepiin, fenobarbitaal, fenütoiin (epilepsiaravimid);
English: The two active substances in Juluca, dolutegravir and rilpivirine, block the actions of enzymes that the HIV needs to make copies of itself in the cells it has infected.
Estonian: Juluca kaks toimeainet, dolutegraviir ja rilpiviriin, blokeerivad selliste ensüümide toime, mis aitavad HIV-il sellega nakatunud rakkudes paljuneda.
English: The studies compared the effectiveness of switching to the combination of dolutegravir and rilpivirine with that of remaining on the current combination of HIV medicines.
Estonian: Uuringutes võrreldi ravi efektiivsust patsientidel, kes läksid üle dolutegraviiri ja rilpiviriini kombinatsioonile, ning patsientidel, kes kasutasid endist HIV-ravimite kombinatsiooni edasi.
English: What benefits of Juluca have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Juluca kasulikkus?
English: Juluca can only be obtained with a prescription and it should be prescribed by doctors experienced in managing HIV infection.
Estonian: Ravi peab välja kirjutama HIV-nakkuse ravis kogenud arst.
English: • dexamethasone given by mouth or by injection (a steroid anti-inflammatory and immunosuppressant medicine) except when used as a single-dose treatment;
Estonian: • suukaudne või süstitav deksametasoon (põletikuvastane ja immuunsupressiivne steroidravim),
English: • St John's wort (a herbal medicine used for treating depression).
Estonian: • naistepuna (taimne depressiooniravim).
English: This is a summary of the European public assessment report.
Estonian: See on Euroopa avaliku hindamisaruande kokkuvõte.
English: This document cannot replace a face-to-face discussion with your veterinarian.
Estonian: See dokument ei asenda vahetut nõupidamist teie loomaarstiga.
English: The vaccine helps to reduce the symptoms of the diseases.
Estonian: Vaktsiin aitab vähendada nende haiguste sümptomeid.
English: The antibodies will help to protect against the diseases caused by these viruses or bacteria.
Estonian: Antikehad aitavad kaitsta haiguste eest, mida need viirused või bakterid põhjustavad.
English: This summary was last updated in January 2015.
Estonian: Kokkuvõtte viimane uuendus: 01-2015.
English: If you need more information about your animal's medical condition or treatment, contact your veterinarian.
Estonian: Kui soovite ravitava looma haigusseisundi või ravi kohta rohkem teavet, pöörduge oma loomaarsti poole.
English: If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Estonian: Kui soovite lisateavet veterinaarravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande osa).
English: They included young and adult cats of various breeds, but not young kittens.
Estonian: Uuringutesse kaasati eri tõugu noored ja täiskasvanud kassid, kuid mitte väikeseid kassipoegi.
English: Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
Estonian: Selles selgitatakse, kuidas veterinaarravimite komitee hinnangu alusel, mis tugineb esitatud dokumentidele, koostati vaktsiini kasutustingimuste soovitused.
English: It can also prevent death due to panleucopenia and prevent FeLV from remaining in the blood.
Estonian: Samuti võib see aidata ära hoida panleukopeeniast põhjustatud surma ja ennetada kasside leukeemia viiruse püsimist veres.
English: What are the precautions for the person who gives the medicine or comes into contact with the animal?
Estonian: Milliseid ettevaatusmeetmeid peab võtma loomale ravimit andev või loomaga kokku puutuv inimene?
English: Information on the prescription status of this product may be found on the label/outer package.
Estonian: Teave selle kohta, kas toode on retseptiravim, on esitatud etiketil/välispakendil.
English: If the kitten has high levels of antibodies received from the mother in the womb and in the milk, the first vaccination should be delayed until 12 weeks of age.
Estonian: Kui kassipojal on emalt üsasiseselt ja piimaga saadud antikehade suur sisaldus, tuleb esmane vaktsineerimine edasi lükata 12. elunädalani.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi looduslikke kaitsemehhanisme) kaitsma organismi haiguse eest.
English: The cat should be revaccinated for all components one year after the first vaccination course, then every year for chlamydiosis and feline leukaemia, and every three years for rhinotracheitis, calicivirosis and panleucopenia.
Estonian: Kass tuleb revaktsineerida kõikide komponentide vastu üks aasta pärast esmast vaktsineerimist ja seejärel igal aastal klamüdioosi ja kasside leukeemia vastu ning iga kolme aasta tagant rinotrahheiidi, kalitsiviroosi ja panleukopeenia vastu.